Inhibrx Biosciences, Inc.
NASDAQ: INXB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Paul Lappe
- Employees
- 166
- Headquarters
- La Jolla, United States
- IPO year
- 2018
- Market cap
- $225.9M
- Website
- https://inhibrx.com
Loading INXB…
Loading profile data…Frequently asked questions about INXB
What does Inhibrx Biosciences, Inc. (INXB) do?
Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials. It i...
Where does INXB trade?
Inhibrx Biosciences, Inc. (INXB) trades on the NASDAQ Global Market.
What sector is INXB in?
Inhibrx Biosciences, Inc. (INXB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inhibrx Biosciences, Inc.?
Mark Paul Lappe is the chief executive officer of Inhibrx Biosciences, Inc. (INXB).
Where is Inhibrx Biosciences, Inc. headquartered?
Inhibrx Biosciences, Inc. is headquartered in United States.
Does INXB pay a dividend?
Inhibrx Biosciences, Inc. (INXB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INXB go public?
Inhibrx Biosciences, Inc. (INXB) completed its initial public offering in 2018.
Is INXB an ADR?
Yes — INXB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Inhibrx Biosciences, Inc. reporting and dividends follow the underlying issuer.